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Abstract
Background Use of topical antibiotics to improve perineal wound healing after abdominoperineal resection (APR)
is controversial. The aim of this systematic review was to determine the impact of local application of gentamicin on
perineal wound healing after APR.
Methods The electronic databases Pubmed, EMBASE, and Cochrane library were searched in January 2015.
Perineal wound outcome was categorized as infectious complications, non-infectious complications, and primary
perineal wound healing.
Results From a total of 582 articles, eight studies published between 1988 and 2012 were included: four ran-
domized controlled trials (RCTs), three comparative cohort studies, and one cohort study without control group.
Gentamicin was administered using sponges (n = 3), beads (n = 4), and by local injection (n = 1). There was
substantial heterogeneity regarding underlying disease, definition of outcome parameters and timing of perineal
wound evaluation among the included studies, which precluded meta-analysis with pooling. Regarding infectious
complications, three of six evaluable studies demonstrated a positive effect of local application of gentamicin: one of
four RCTs and both comparative cohort studies. Only two RCTs reported on non-infectious complications, showing
no significant impact of gentamicin sponge. All three comparative cohort studies demonstrated a significantly higher
percentage of primary perineal wound healing after local application of gentamicin beads, but only one out of three
evaluable RCTs did show a positive effect of gentamicin sponges.
Conclusion Currently available evidence does not support perineal gentamicin application after APR.
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Introduction
Impaired perineal wound healing after abdominoperineal
resection (APR) is a clinically significant problem. Perineal
wound infection, wound dehiscence, and deep pelvic
abscess are frequently encountered complications, which
often require intensive and long-lasting wound care and
interfere with quality of life. Furthermore, modified
approaches for distal rectal cancer have increased the
incidence of perineal wound problems after APR, espe-
cially the use of neo-adjuvant radiotherapy [1]. Surgical
site infections, like perineal wound infection, may result in
prolonged hospitalization, readmission, increase in health
care costs, and even an increase in mortality [2]. The
cornerstone in the prevention of wound infection is the use
of systemic and/or oral prophylactic antibiotics. Despite
prophylactic antibiotics, perineal wound infection has been
reported to occur in more than half of the patients who
undergo an APR after neo-adjuvant radiotherapy for rectal
cancer [3]. For the antibiotics to be effective, a high
antibiotic concentration at the designated site is warranted.
However, systemic administration hardly effects perineal
wound healing. This is most likely due to dead space with
retention of fluids and surgically impaired blood supply.
Perineal application leads to high local concentrations with
low serum levels and hence low systemic adverse reactions
[4]. In general, local gentamicin application is regarded as
safe, easy to use, and inexpensive [5]. However, there is
still no consensus on the clinical value of topical gentam-
icin to improve perineal wound healing in patients under-
going APR. Therefore, we conducted a systematic review
of the literature on the effect of local gentamicin in pre-
venting perineal wound infection and improving perineal
wound healing after APR.
Methods
Search strategy
All studies evaluating the impact of local application of
gentamicin on perineal wound healing after APR were
considered eligible. Inclusion was not restricted to study
design (i.e., randomized controlled trial (RCT), prospective
or retrospective cohort study (with or without control
group), and underlying disease (i.e., rectal cancer, anal
cancer, and inflammatory bowel disease). Animal studies,
systematic reviews, non-English articles, case series (\5
patients), and congress abstracts were excluded. Studies
were identified by searching electronic databases and
scanning of reference lists. This search was applied in
PubMed (1971–2015), EMBASE (1982–2015), and
Cochrane library (2005) databases in January 2015. The
following medical subject heading (MESH) terms were
used; gentamicin, aminoglycosides, anti-bacterial agents,
perineum, abdomen, colorectal surgery, surgical proce-
dures operative, and general surgery. Other search terms
were abdominal perineal resection, abdominoperineal
resection, abdominoperineal excision, abdominal perineal
excision, perineum surgery, perineal surgery, gentamicin,
gentamycin, aminoglycoside antibiotics, and local antibi-
otics. No language or publication date restrictions were
applied. The candidate publication titles and abstracts were
screened to exclude non-related publications. Secondly, the
full text of the remaining manuscripts was read to deter-
mine whether they were eligible for inclusion.
Validity assessment and assessment of eligibility
Methodological quality and risk of bias were assessed for
the included studies. For cohort studies, the Newcastle
Ottawa quality assessment scale for cohort studies was
used to assess risk of bias [6]. The quality items scored
were as follows: representativeness of the exposed cohort,
selection of the non-exposed cohort, ascertainment of
exposure, the absence of outcome of interest at the start of
the study, validity of the design or analysis, assessment of
outcome, duration of follow-up, and lost to follow-up. For
RCTs, the Jadad scoring system was used to assess the risk
of bias [7].
Data extraction and data analysis
Data were extracted from the included studies by two
independent investigators (GM, PT). Disagreements were
resolved by discussion between the two reviewers. For
each article, the following data were collected: year of
publication, study design, number of patients, underlying
disease, comorbidities, type of APR, neo-adjuvant radio-
therapy, perineal closure technique, perineal drainage,
systemic antibiotic use, administration method and dosage
of locally applied gentamicin, definitions of outcome
parameters, follow-up period, type and incidence of per-
ineal wound complications, primary perineal wound heal-
ing rate, reoperation rate, and hospital stay. Meta-analysis
was not intended because of the heterogeneity among
studies regarding study population, variety in gentamicin
application, and non-uniform definitions of outcome
parameters.
Results
The systematic search resulted in a total of 582 articles.
After removal of duplicates among the different databases,
527 articles remained. After screening of publication titles
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and abstracts, 17 publications were retrieved for full text
review. Of these 17 publications, 10 studies were excluded,
because gentamicin was not placed in the perineal wound
(n = 3) [8–10], no separate data for perineal and abdomi-
nal wound outcome were provided (n = 4) [11–14], sur-
gery was not an APR procedure (n = 1) [15], use of
bacitracin spray instead of gentamicin (n = 1) [16], and the
type of local antibiotic was not described (n = 1) [17]. One
additional study was included after crosschecking refer-
ence lists of the included studies. In total, eight studies
were included of which four were RCTs, three were
comparative cohort studies, and the remaining study was a
non-comparative cohort study. After exclusion of patients
who underwent non-APR surgery from two cohort studies
[18, 19], a total number of 602 patients were included in
this systematic review. The risk of bias of the included
studies is displayed in ‘‘Appendix’’.
Patient characteristics
Patient characteristics of each included study are displayed
in Table 1. APR was performed for cancer in 68 %
(n = 381) of the patients, whichwas primary rectal cancer in
82 % (n = 311; five studies) [19–23], anal cancer in 4 %
(n = 15; two studies) [20, 23], locally recurrent rectal or anal
cancer in 1 % (n = 4; one study) [20], sarcoma in one patient
[20], and unspecified type of cancer in 13 % (n = 50; two
studies) of the patients [16, 24]. In three studies, patients with
inflammatory bowel disease were also included with a
specified number of patients in two studies (total n = 46)
[18, 20, 24]. In the remaining patients, APR was performed
for incontinence [20], villous adenoma [24], or unspecified
diseases [18, 25]. Comorbidities related to risk of wound
infection were described in two studies [21, 22]. Use of neo-
adjuvant radiotherapywas described in three studies andwas
given to 21 % (n = 115) of the included patients [20–22].
Type of neo-adjuvant radiotherapy was only specified in one
study (5 9 5 Gy) [21]. One study described prior pelvic
radiotherapy in four patients [20].
Surgery and prophylactic antibiotics
The different types of surgery being performed in the
included studies are specified in Table 1. None of the
studies described the use of an omental plasty. Primary
perineal wound closure was performed in all studies, of
which four studies mentioned closure in multiple layers
[20–23]. Routine pelvic drainage was described in seven
studies [18, 19, 21–25], and a perineal drain was selectively
placed in one study [19]. Type of drainage differed among
study groups in one study, with irrigation-suction drainage
in the control group, and either continuous or intermittent
drainage in the local gentamicin beads group [25].
Considering the type of local administration of gen-
tamicin at the perineal wound, a collagen carrier was used
in three studies [20–22], gentamicin beads were used in
four studies [18, 19, 23, 25], and gentamicin was locally
injected in one study (Table 2) [24]. Dosage of locally
applied gentamicin was provided in four studies. A total
dose of 210 mg [22], 200 mg [20], and 160 mg [24] was
used in three studies. In the remaining study, the concen-
tration of gentamicin was measured in the wound fluid with
a mean value of 138.1 lg/l (n = 7, standard deviation
58.4) at day one post-operatively [23]. Four studies
described placement of the local antibiotic in the sacral
cavity [21–23, 25], while a more superficial application in
the perineal wound was reported in the other four studies
[18–20, 24]. Seven of eight studies described routine use of
different regimens of prophylactic pre-operative antibi-
otics, and five studies also continued prophylactic antibi-
otics post-operatively, only in a subgroup of patients in one
of these five studies (Table 2).
Perineal wound outcome
Perineal wound outcome parameters were defined in six
out of eight included studies, all being different among
these six studies (Table 3). Time points for wound evalu-
ation were provided in five studies, which were also not
uniform.
Perineal wound outcome was categorized as infectious
complications, non-infectious complications, and primary
wound healing for the purpose of this review (Table 3).
Regarding infectious complications, three of six evaluable
studies demonstrated a positive effect of local application
of gentamicin. This significant difference was found in one
out of four RCTs [22], and both comparative cohort studies
[21, 25]. The impact on infectious complications was found
in two out of three studies using gentamicin sponge [21,
22] and in one out of two studies using gentamicin beads
[25].
Regarding non-infectious complications (i.e., seroma,
hematoma, and dehiscence without infection), only two
studies uniformly reported this outcome parameter. These
two RCTs did not report a significant impact of gentamicin
sponge on this perineal wound outcome parameter [20, 22].
One additional comparative cohort study reported a sig-
nificant difference in the incidence of persistent perineal
fistula in favor of gentamicin beads [25], although a fistula
may be also considered as a long-term consequence of an
initial infectious problem.
Primary perineal wound healing was the most consis-
tently reported outcome parameter among seven included
studies, including six comparative studies. However, the
RCT of Collin et al. demonstrates that this outcome
parameter is highly dependent on the time point of
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evaluation, ranging from 82 % after 7 days to 47 % after
1 month in the control group [20]. All three comparative
cohort studies demonstrated a significantly higher per-
centage of primary perineal wound healing after local
application of gentamicin [19, 21, 25], but only one out of
three evaluable RCTs did show a positive effect of local
gentamicin [23]. The positive effect of local gentamicin on
primary wound healing was found in one out of three
studies using sponges [21] and in all three comparative
studies using beads [19, 23, 25]. Significant improvements
in perineal wound outcome after local gentamicin were
only observed in homogenous cancer populations, while
the two RCTs containing subgroups of patients with IBD
were both negative [20, 24].
Reoperation and hospital stay
The reoperation rate for perineal wound infection was
described in three studies and ranged between 2 and 5 %
for the local application of gentamicin and ranged between
0 and 9 % when no topical antibiotics were applied [20, 22,
23]. Hospital stay was described in six studies (Table 3)
[18, 20, 21, 23–25]. Out of five comparative studies, three
studies reported a significant reduction in hospital stay
(p\ 0.05) [21, 23, 25]. The mean reduction in hospital
stay was at least 7 days [21, 23, 25].
Discussion
The present systematic review of the literature on perineal
application of gentamicin after APR reveals that only a
limited number of randomized and comparative cohort
studies have been published, which are all of relatively low
quality. Five of eight included studies were published more
than 20 years ago. Most RCTs did not perform a power
calculation and can be considered underpowered. Substan-
tial heterogeneity was observed among the studies regarding
Table 2 Use of local and systemic antibiotics in patients undergoing APR with primary perineal closure
Included
studies
n Local antibiotics Systemic antibiotics
First author Local
(Yes/no)
Type Location Pre-operative Post-operative
Collin et al.
[7]
52 Yes Genta sulfate sponge 2.0 mg/m2
(Collatamp)
Perineal
wound
Prophylaxis not specified Not specified
n (%): 11 (21)
50 No – – Prophylaxis not specified Not specified
n (%): 11 (22)
De Bruin
et al. [8]
19 Yes Genta sponge (Garacol), 3 per
patient
Sacral
cavity
Augmentin 1 9 1000/
200 mg
–
21 No – – Augmentin 1 9 1000/
200 mg
–
Gruessner
et al. [11]
49 Yes Genta sponge (Septocoll), 3 per
patient
Sacral
cavity
Cefa 1 9 2 g, metro
1 9 500 mg
–
48 No – – Cefa 1 9 2 g, metro
1 9 500 mg
–
Rosen et al.
[27]
22 Yes Genta-PMMA, 30 beads, 1 chain
per patient
Sacral
cavity
Cefa 1 9 2 g, metro
1 9 500 mg
Cefa 2 9 2 g, metro
2 9 500 mg; day of operation
22 No – – Cefa 1 9 2 g, metro
1 9 500 mg
Cefa 2 9 2 g, metro
2 9 500 mg; day of operation
Moesgaard
et al. [17]
41 Yes Injection 160 mg genta/400 mg
metro
Perineal
wound
Genta 1 9 80 mg, metro
1 9 500 mg
Genta 3 9 80 mg, metro
3 9 500 mg; 2 days
38 No – – Genta 1 9 80 mg, metro
1 9 500 mg
Genta 3 9 80 mg, metro
3 9 500 mg; 2 days
Sachweh
et al. [30]
80 Yes Genta-PMMA, 30 beads, 2 chains
per patient
Sacral
cavity
– –
26 No – – – –
Mu¨hleder
et al. [19]
67 Yes Genta-PMMA, 1 chain per patient Perineal
wound
Paro 4 9 500 mg, metro
3 9 500 mg orally
Metro 3 9 500 mg; 3 days
42 No – – – –
Lu¨tje et al.
[15]
25 Yes Genta PMMA 30-beads
(Septopal), 1 chain per patient
Perineal
wound
Latamoxef 1 9 2 g Latamoxef 1 9 2 g 12 h after
incision
Cefa cefazolin, Metro metronidazole, Paro paromomycin, Genta gentamicin
2790 World J Surg (2015) 39:2786–2794
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underlying disease, surgical techniques, type of administra-
tion of gentamicin, antibiotic dosage, and peri-operative use
of systemic antibiotics, definitions of outcome parameters,
and timing of perineal wound evaluation. In addition, the
non-randomized comparative studies have a substantial risk
of bias. Taking all these methodological shortcomings in
mind, we conclude that there is no convincing evidence for
routine perineal application of gentamicin after APR. Sta-
tistically significant differences in favor of local gentamicin
were mainly observed in comparative cohort studies, while
themajority of RCTswere negative for bothwound infection
and primary wound healing.
In contrast to the present study, a recent systematic review
showed that local application of gentamicin in all clean and
clean contaminatedwounds significantly reduces surgical site
infections [26]. For patients undergoing colorectal surgery,
several studies reported a positive effect of local gentamicin
[10, 13]. However, gentamicin was mostly applied to the
abdominal wound in these studies, without reporting on the
use of topical antibiotics at the perineal wound with corre-
sponding outcome. There are several potential reasons for a
difference in wound healing between abdominal and perineal
wounds, for example, with regard to the degree of bacterial
contamination, tension on wound edges, and the received
radioactivity dose in case of neo-adjuvant treatment [27, 28].
In addition, fluid may collect in the dead space above the
closed perineum, and may become secondarily infected, with
subsequent drainage through the perineum. The abdominal
pressure on the perineal wound after (partially) resecting the
pelvic floor may also negatively influence perineal wound
healing. Because of these differences, our systematic review
specifically focused on the perineal wound.
There are several patients and surgery-related factors
influencing perineal wound healing after APR. Although the
majority of patients were diagnosed with cancer, inflam-
matory bowel disease was also included in three studies.
Inflammatory bowel disease patients significantly differ
from cancer patients regarding perineal wound healing due
to malnutrition, chronic pelvic inflammation, use of
immunosuppressive medication, and pre-existing perineal
fistulas and sinuses [29]. On the other hand, the use of pre-
operative radiotherapy in rectal cancer patients may affect
wound healing significantly [1]. Surgical techniques may
also influence the occurrence of perineal wound infection
and subsequent perineal wound healing. The omentum, for
instance, is a major contributor to the local immune response
and has the ability to promote angiogenesis [30, 31].
Therefore, placing an omental plasty in the pelvic cavity has
been suggested to improve primary perineal wound healing
[32]. Besides an omental plasty, several types of musculo-
cutaneous or perforator flaps can be used for closure of the
pelvic defect in selected patients undergoing extensive
resection (i.e., exenterations) or salvage surgery for analT
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cancer [33–35]. None of the patients in the included studies
underwent flap reconstruction, and the use of omental plasty
was not specified. Therefore, the additive value of local
gentamicin in combination with an autologous tissue flap or
omental plasty is unknown. Furthermore, none of the
included studies described laparoscopic surgery, the use of
vessel sealing equipment, or patient positioning which have
been shown to be related to blood loss, operative time, and
risk of surgical site infection. These procedural characteris-
tics may be of influence on perineal wound healing and may
hamper extrapolation of results of the present systematic
review to current clinical practice [24, 36].
Among the different application techniques, sponges,
beads, and injection differ in local gentamicin concentra-
tion and release over time [4]. Besides differences in local
antibiotic concentration, the collagen from which the
gentamicin is delivered can have an influence on perineal
wound healing itself [37]. This is most likely due to faster
hemostasis and the protective effect on seroma and
hematoma formation, which ultimately could affect pri-
mary perineal wound healing [37].
Gentamicin is most effective against gram-negative
bacteria and some gram-positive bacteria, with the excep-
tion of anaerobe bacteria. Nelson et al. described in a
systematic review of 182 RCTs that the addition of
antibiotics against anaerobe bacteria in colorectal surgery
reduces surgical site infections [38]. Based on these data,
an antibiotic that is effective against anaerobic bacteria is
currently most often being added as pre-operative pro-
phylaxis [39]. However, antibiotics effective against
anaerobe bacteria are most often not locally applied in a
sustained matter and combined with gentamicin. Therefore,
the local application of gentamicin in combination with an
antibiotic targeting anaerobe bacterium might enhance the
effectiveness against perineal wound problems.
In conclusion, a restricted number of low-quality ran-
domized and non-randomized studies do not convincingly
show a positive effect of local gentamicin on perineal
wound infection or primary wound healing rate. APR for
benign and malignant disease is essentially different, and
treatment of distal rectal cancer has changed significantly
since publication of most of the included studies. This
underlines the need for new RCTs on locally applied
gentamicin in more representative and homogeneous
patient groups. At present, available literature does not
support the routine use of local gentamicin application for
perineal wound healing following APR.
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Appendix
See Table 4.
Table 4 Assessment risk of bias
Included Studies Jadad et al. [14] (0–5) Newcastle Ottawa quality assessment scale [38] cohort studies
Selection (0–4) Comparability (0–2) Outcome (0–3) Total (0–9)
Collin et al. [7] 2 – – – –
De Bruin et al. [8] – 2 – 1 3
Gruessner et al. [11] 1 – – – –
Rosen et al. [27] 1 – – – –
Lu¨tje et al. [15] – 1 – 1 2
Sachweh et al. [30] – 1 – 1 2
Mu¨hleder et al. [19] – 1 – 1 2
Moesgaard et al. [17] 2 – – – –
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